Mesoblast Ltd. (MSB) reported that it has completed patient recruitment in the events-driven Phase 3 trial of its product candidate Revascor (MPC-150-IM) for advanced chronic heart failure. The late-stage study is evaluating whether Revascor reduces recurrent non-fatal heart failure-related major adverse cardiac events (HF-MACE), and prevents or delays terminal cardiac events (TCEs), defined as cardiovascular death, heart transplant or placement of an artificial device, over at least 12 monthshttp://crweworld.com/article/news-provided-by-globenewswire/929465/phase-3-trial-of-mesoblasts-cell-therapy-in-chronic-heart-failure-completes-recruitment
Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-52
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.025(2.22%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.13 | $396.3K | 346.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 44675 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 493 | 3 |
View Market Depth
| Last trade - 10.13am 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |